Evidence map›Paper›PMID 41410746›Full record

ArticleCancer immunology, immunotherapy : CII2025

Identification of HLA class II-restricted T cell receptors against shared PIK3CA mutations in patients with epithelial cancers.

S M Rafiqul Islam, Samantha Seitter, Maria Parkhurst, Frank J Lowery, Miaki Fukuhara, Sanghyun P Kim, Noam Levin, Jared J Gartner, Satyajit Ray, Todd Prickett and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Shared neoantigens for cancer immunotherapy.Molecular therapy. Oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

S M Rafiqul Islam *National Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0009-0001-0037-2766
Samantha Seitter *National Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3193-8718
Maria ParkhurstNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-7231-5069
Frank J LoweryNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4620-5293
Miaki FukuharaNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5545-5999
Sanghyun P KimNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9519-1994
Noam LevinNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0664-2808
Jared J GartnerNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2924-3519
Satyajit RayNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3260-5982
Todd PrickettNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5466-4150
Victoria HillNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2214-2459
Paul F RobbinsNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1260-8123
Stephanie L GoffNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3317-9804
Steven A RosenbergNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA. sar@mail.nih.gov.ORCID http://orcid.org/0000-0002-8939-8910
Nikolaos ZacharakisNational Cancer Institute, Surgery Branch, National Institutes of Health, Bethesda, MD, USA. zacharakisn@nih.gov.ORCID http://orcid.org/0000-0001-7103-5591

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PIK3CA is the third most common mutated gene in epithelial cancers, behind only TP53 and KRAS. Somatic PIK3CA mutations occur predominantly in the protein's hotspot locations H1047, E545, E542 and N345, and evidence of those alterations eliciting immune responses has been limited. HLA class I-restricted TCRs against E545K and H1047L have, only recently, been identified following in vitro sensitization (IVS) with peripheral blood lymphocytes (PBL) from normal donors. In this study, we examined the immunogenicity of PIK3CA in patients with epithelial cancers of diverse histology, by testing TIL and antigen-experienced PBL against autologous hotspot PIK3CA mutations. Two distinct TCRs specific to PIK3CA

Indexed as

Histocompatibility Antigens Class IIMutationPhosphatidylinositol 3-KinasesReceptors, Antigen, T-CellClass I Phosphatidylinositol 3-KinasesFemaleHumansLymphocytes, Tumor-InfiltratingMaleClass I Phosphatidylinositol 3-KinasesHistocompatibility Antigens Class IIPhosphatidylinositol 3-KinasesPIK3CA protein, humanReceptors, Antigen, T-CellimmunotherapyPIK3CAT cellTCR

Identifiers

PMID41410746
PMCPMC12715084

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.